Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
Rattachement africain : br, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
To control and decrease the public health impact of human protozoan diseases such as Chagas disease, leishmaniasis, and human African trypanosomiasis, expediting the development of new drugs and vaccines is necessary. However, this process is filled with difficulties such as highly complex parasite biology and disease pathogenesis and, as typical for neglected tropical diseases, comparatively limited funding for research and development. Thus, in vitro and in vivo study models that can sufficiently reproduce infection and disease key features while providing rational use of resources are essential for progressing research for these conditions. One example is the in vivo bioluminescence imaging (BLI) mouse model for Chagas disease, which provides highly sensitive detection of long wavelength light generated by Trypanosoma cruzi parasites expressing luciferase. Despite this technique becoming the standard approach for drug efficacy in vivo studies, research groups might still struggle to implement it due to a lack of proper practical training on equipment handling and application of quality control procedures, even when suitable BLI equipment is readily available. Considering this scenario, this protocol aims to guide from planning experiments to data acquisition and analysis, with details that facilitate the implementation of protocols in research groups with little or no experience with BLI, either for Chagas disease or for other infectious disease mouse models.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
- Date Crossref
- 31/05/2024
- Éditeur
- MyJove Corporation
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Universidade de São Paulo Instituto de Ciências Biomédicas (ICB) pays non établi dans la noticeUniversité ou école supérieure
-
Drugs for Neglected Diseases Initiative pays non établi dans la noticeOrganisation à but non lucratif
-
Universidade Federal de São Paulo Programa de Pós-Graduação em Microbiologia e Imunologia pays non établi dans la noticeUniversité ou école supérieure
-
Instituto de Ciências Farmacêuticas pays non établi dans la noticeStructure de recherche
Instituto de Ciências Biomédicas (ICB) — Universidade de São Paulo, Drugs for Neglected Diseases Initiative et Programa de Pós-Graduação em Microbiologia e Imunologia — Universidade Federal de São Paulo, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.